Page 5,986«..1020..5,9855,9865,9875,988..6,0006,010..»

Stem Cell Research Religious Controversy – Video

Posted: Published on December 12th, 2012

Stem Cell Research Religious Controversy Stem Cell Research short documentary for my LTV FinalFrom:Kent TorViews:6 0ratingsTime:05:33More inEducation See the original post: Stem Cell Research Religious Controversy - Video … Continue reading

Posted in Stem Cell Research | Comments Off on Stem Cell Research Religious Controversy – Video

Regenetek Research Inc. Launches New Intelligent Software for Therapeutic Stem Cell Trials

Posted: Published on December 12th, 2012

WINNIPEG, Manitoba, Dec. 11, 2012 /PRNewswire/ -- Doug Broeska, Ph.D., CEO of Regenetek Research Inc., an international medical research company with offices in Canada and India has announced that they are launching new web-based, self-managing, clinical trial software that amongst other things will be able to extend patient Registry information into individual patient case studies and aggregate the data with comparisons to cohorts. The company has so far specifically focused their new technology on a number of autologous therapeutic stem cell trials for a range of neurologic diseases that are taking place in multiple centers worldwide. Such software would have important application where limited financial resources are combined with the need to validate efficacy and prove reproducibility of therapy protocols. "The ability to rigorously evaluate individual patients, monitor adverse events, and aggregate data from different patients in different centers while maintaining ethical standards will achieve better control of bias, generate greater statistical power, and produce more meaningful conclusions for clinical outcomes," says Dr. Broeska, CEO of Regenetek Research. Indeed, for cases where every patient's cells are unique, randomized controlled trials are simply not possible as an appropriate design for clinical investigation. "This is just getting back to the basics of … Continue reading

Posted in Stem Cell Research | Comments Off on Regenetek Research Inc. Launches New Intelligent Software for Therapeutic Stem Cell Trials

Stem Cell Therapy and Medical Tourism: Of Promise and Peril? – Video

Posted: Published on December 12th, 2012

Stem Cell Therapy and Medical Tourism: Of Promise and Peril? From:harvardstemcellViews:9 0ratingsTime:01:15:50More inScience Technology See more here: Stem Cell Therapy and Medical Tourism: Of Promise and Peril? - Video … Continue reading

Comments Off on Stem Cell Therapy and Medical Tourism: Of Promise and Peril? – Video

Potential gene therapy approach to sickle cell disease highlighted at ASH

Posted: Published on December 12th, 2012

Proof-of-concept animal study selected as one of the best presentations at 54thAmerican Society of Hematology Annual Meeting and Exposition BOSTON, Dec. 11, 2012 /PRNewswire-USNewswire/ -- Researchers at Dana-Farber/Children's Hospital Cancer Center (DF/CHCC) have taken the first preliminary steps toward developing a form of gene therapy for sickle cell disease. In an abstract presented on Dec. 10 at the 54th annual meeting of the American Society of Hematology, the research teamled by DF/CHCC's Raffaele Renella, MD, PhD, Stuart H. Orkin, MD, and David A. Williams, MDannounced that they had demonstrated in an animal model the feasibility of activating a form of hemoglobin unaffected by the sickle cell mutation. The study was included as part of the meeting's Best of ASH session on Dec. 11. At this session, the meeting's scientific co-chairs present what they consider to be the best abstracts of the 4,000-plus presented at the conference. "This work builds on the transformative basic research discovery of the role of BCL11A in maintaining fetal hemoglobin silencing by the Orkin laboratory with a near-term goal of curing sickle cell disease using gene therapy," said Williams, chief of the Division of Hematology/Oncology at DF/CHCC and senior author on the abstract. "We have had … Continue reading

Comments Off on Potential gene therapy approach to sickle cell disease highlighted at ASH

Photo Release — GIOSTAR and the Government of India to Enter $2 Billion Stem Cell Therapy Program – Official State …

Posted: Published on December 12th, 2012

SAN DIEGO, Dec. 10, 2012 (GLOBE NEWSWIRE) -- The Global Institute Of Stem-cell Therapy And Research (GIOSTAR) announced today a collaborative treatment plan to serve the local population suffering from a genetic disease, Sickle Cell Anemia. President and CEO, Mr. Deven Patel and his team met with Honorable Chief Minister Shri Arjun Munda of State of Jharkhand, India in November 2012 to address the local population's medical needs. A photo accompanying this release is available at http://www.globenewswire.com/newsroom/prs/?pkgid=16184. As a follow-up, a government delegation representing the state of Jharkhand, India; Chief Minister, Principal Health Secretary, Chief Secretary and many other officials are visiting GIOSTAR in San Diego on December 14, 2012 to finalize the proposed two (2) billion U.S. dollar contract to be serviced over the next 15 years. Bob Filner, Mayor of San Diego and City Council Members are among the invited guests for this state visit along with representatives from Belize and the island nation of Saint Vincent and the Grenadines. Two hundred (200) jobs are estimated to be created in San Diego and it is expected that the dialog would include an economic development program between City of San Diego and State of Jharkhand, India. GIOSTAR is a … Continue reading

Comments Off on Photo Release — GIOSTAR and the Government of India to Enter $2 Billion Stem Cell Therapy Program – Official State …

Nano-TMII move Time lapse – Video

Posted: Published on December 12th, 2012

Nano-TMII move Time lapse Mount Sinai's Nanomedicine Lab has moved to the Hess Center for Science and MedicineFrom:wjmmulderViews:0 0ratingsTime:01:52More inScience Technology Read more here: Nano-TMII move Time lapse - Video … Continue reading

Comments Off on Nano-TMII move Time lapse – Video

Global Nanotechnology Industry

Posted: Published on December 12th, 2012

NEW YORK, Dec. 11, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue: Global Nanotechnology Industry http://www.reportlinker.com/p0326269/Global-Nanotechnology-Industry.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Nanotechnology This report analyzes the Global market for Nanotechnology in US$ Billion by the following End-Use Sectors: Chemicals, Automotive, Aerospace & Defense, Semiconductors & Electronics, Pharma & Healthcare, Food, and Others. Annual estimates and forecasts are provided for the period 2009 through 2018.The report profiles 670 companies including many key and niche players such as Advanced Diamond Technologies, Inc., Advanced Nano Products Company Limited, Altair Nanotechnologies Inc., Arrowhead Research Corporation., Calando Pharmaceuticals, Inc., Bruker Corporation, Catalytic Materials, LLC, Chemat Technology Inc., eSpin Technologies, Inc., ELITech Group, Genefluidics, Inc., Hanwha Nanotech Corporation, Hybrid Plastics, Hyperion Catalysis International, Inc., Integran Technologies, Inc., Intrinsiq Materials Limited, Life Technologies Corportation, Luxtera, Inc., Nanocyl S.A., NanoGram Corporation, NanoMaterials Ltd., Nanosys, Inc., Quantumsphere, Inc., Raymor Industries, Inc., Rogue Valley Microdevices, Inc., Shenzhen Nanotech Port Co., Ltd., SouthWest NanoTechnologies, Inc., Starpharma Holdings, Dendritic Nanotechnologies, Inc., Teledyne Scientific & Imaging, LLC, and Unidym, Inc. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based upon search engine sources in the public domain. I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS Study … Continue reading

Comments Off on Global Nanotechnology Industry

Spine Doctor Offers Innovative Non-Surgical Procedure

Posted: Published on December 12th, 2012

Dr. Issada Thongtrangan, with Valley Orthopedics, is offering a new service utilizing Adult Stem Cells and Platelet Rich Plasma (PRP) to treat spine, orthopedic conditions and musculoskeletal injuries in indicated patients. Pheonix, AZ (PRWEB) December 11, 2012 Dr. Issada Thongtrangan, with Valley Orthopedics, is offering a new service utilizing Adult Stem Cells and Platelet Rich Plasma (PRP) to treat spine, orthopedic conditions and musculoskeletal injuries in indicated patients. Dr. Thongtrangan has begun offering Adult Stem Cell Therapy and PRP Therapy for orthopedic and spine conditions at his Valley Orthopedic locations in Phoenix, Goodyear and Deer Valley. Some of the many conditions regenerative stem cell therapy can help treat include tendonitis, muscle injury, non-healing fractures, degenerative disc disease, degenerative facet arthritis, piriformis syndrome, paraspinal trigger point, spinal nerve injury, degenerative knee disease, degenerative hip disease, and degenerative joint diseases in appropriate candidates. In order to repair damaged tissue, mesenchymal adult stem cells are taken from a patients bone marrow, fat tissue and blood. The stem cells are then redistributed in concentrated amounts to the problem area, to repair or regenerate diseased or damaged cells. The procedure is performed on an outpatient basis and takes approximately one hour or less. It is … Continue reading

Posted in Mesenchymal Stem Cells | Comments Off on Spine Doctor Offers Innovative Non-Surgical Procedure

Seattle Genetics Highlights ADCETRIS® (Brentuximab Vedotin) Data in Relapsed Hodgkin Lymphoma and Other CD30-Positive …

Posted: Published on December 11th, 2012

ATLANTA--(BUSINESS WIRE)-- Seattle Genetics, Inc. (SGEN) today summarized ADCETRIS (brentuximab vedotin) data in relapsed Hodgkin lymphoma (HL) and other CD30-positive malignancies from multiple presentations at the 54th American Society of Hematology (ASH) Annual Meeting and Exposition being held December 8-11, 2012 in Atlanta, GA. Highlights include compelling survival data from long-term follow up in a pivotal clinical trial of ADCETRIS in relapsed or refractory HL and a retrospective comparison of overall survival among patients treated with ADCETRIS to those not treated with ADCETRIS following an autologous stem cell transplant (ASCT). In addition, data describe the activity and tolerability of ADCETRIS in the salvage HL setting from an investigator-sponsored trial and in relapsed patients age 60 or over with CD30-positive malignancies, including HL. ADCETRIS is an antibody-drug conjugate (ADC) directed to CD30, a defining marker of classical HL. "There are more than a dozen data presentations at ASH evaluating the use of ADCETRIS in CD30-positive malignancies and we are very encouraged by both the broad application across multiple hematologic disease areas as well as the encouraging activity associated with ADCETRIS, said Clay B. Siegall, Ph.D., President and Chief Executive Officer of Seattle Genetics. The extensive investigator and corporate data presentations at … Continue reading

Posted in FDA Stem Cell Trials | Comments Off on Seattle Genetics Highlights ADCETRIS® (Brentuximab Vedotin) Data in Relapsed Hodgkin Lymphoma and Other CD30-Positive …

Seattle Genetics Reports Data from Phase I Trial of ADCETRIS® (Brentuximab Vedotin) in Front-line Hodgkin Lymphoma at …

Posted: Published on December 11th, 2012

ATLANTA--(BUSINESS WIRE)-- Seattle Genetics, Inc. (SGEN) today announced results from a phase I clinical trial of ADCETRIS (brentuximab vedotin) in combination with chemotherapy for the treatment of newly diagnosed advanced stage Hodgkin lymphoma (HL) patients. The data were presented at the 54th American Society of Hematology (ASH) Annual Meeting and Exposition being held December 8-11, 2012 in Atlanta, GA. ADCETRIS is an antibody-drug conjugate (ADC) directed to CD30, a defining marker of classical HL. ADCETRIS is currently not approved for use in the front-line treatment of HL. In the phase I trial, newly diagnosed patients received ADCETRIS concomitantly with either ABVD (Adriamycin, bleomycin, vinblastine and dacarbazine) or AVD, which removes bleomycin from the regimen. At the end of front-line therapy, 24 of 25 patients (96 percent) treated with ADCETRIS plus AVD and 21 of 22 (95 percent) patients treated with ADCETRIS plus ABVD had a complete remission. None of the patients treated in the ADCETRIS plus AVD cohort experienced pulmonary toxicity, compared with an expected rate of pulmonary toxicity caused by ABVD alone of 10-25 percent. The trial was designed to establish the safety profile and maximum tolerated dose when adding ADCETRIS to ABVD or AVD. Antitumor activity was assessed … Continue reading

Posted in FDA Stem Cell Trials | Comments Off on Seattle Genetics Reports Data from Phase I Trial of ADCETRIS® (Brentuximab Vedotin) in Front-line Hodgkin Lymphoma at …

Page 5,986«..1020..5,9855,9865,9875,988..6,0006,010..»